Drugs / TL938
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06589830 | May 2025 → Oct 2026 expected | metastasis from malignant tumor of colon | Suzhou Teligene Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TL938 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06589830 ↗ |
| Route | Oral | “Oral administration” NCT06589830 ↗ |